
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NAR-001
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : NanoRetinal
Deal Size : Undisclosed
Deal Type : Partnership
GBI Partners with NanoRetinal to Advance Vision-Restoring Therapy for Retinal Diseases
Details : The partnership to develop and manufacture NAR-001, NanoRetinal's proprietary nanoparticle technology designed to restore and/or preserve vision in patients with Inherited Retinal Diseases (IRD).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 09, 2025
Lead Product(s) : NAR-001
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : NanoRetinal
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 4A10
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Allterum Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
GBI Biomanufacturing And Allterum Collaborate on Therapeutic Antibody Trials
Details : The collaboration aims to advance Allterum's lead candidate 4A10, a monoclonal antibody (mAb) targeting CD127, a receptor expressed by a broad variety of cancers, into clinic.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 07, 2024
Lead Product(s) : 4A10
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Allterum Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
